Glaxosmithkline Pharmaceuticals peers

Companies like Glaxosmithkline Pharmaceuticalslatest year

Market cap and P/E at the last close; sales growth is the latest quarter on the same quarter a year before; ROE for the latest financial year.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

GLAXO₹2,498.00

Glaxosmithkline Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersPFIZERABBOTINDIAMEDANTAANTHEMAJANTPHARMIPCALABGLENMARKBIOCONMcap ₹42,319 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
GLAXO
FY26
PFIZER
FY26
ABBOTINDIA
FY26
MEDANTA
FY26
Peer
Average
Valuation — at last close
P/E◆ 45.82×——61.95×61.95× -26%
P/B18.66×——◆ 8.70×8.70× +114%
EV/EBITDA◆ 30.21×——37.60×37.60× -20%
Market Cap₹42,319 Cr——₹34,473 Cr₹34,473 Cr +23%
Growth
Revenue CAGR 3Y5.53%1.29%9.01%◆ 17.85%9.38% -41%
Revenue CAGR 5Y3.62%2.39%◆ 9.96%—6.18% -41%
Net Income CAGR 3Y19.26%5.01%17.80%◆ 19.33%14.05% +37%
Revenue YoY (latest Q)16.55%——◆ 26.50%26.50% -38%
Net Income YoY (latest Q)◆ 15.69%——-1.09%-1.09% +1539%
Profitability
EBITDA Margin34.26%◆ 35.88%27.31%20.84%28.01% +22%
Net Income Margin27.11%◆ 28.67%22.40%12.56%21.21% +28%
Return on Common Equity◆ 49.11%17.16%34.46%15.15%22.26% +121%
Return on Capital Employed◆ 52.35%19.60%38.09%14.78%24.16% +117%
Return on Assets24.57%14.69%◆ 24.99%10.38%16.69% +47%
Credit & Quality
Total Debt/Equity◆ 0.00×0.00×—0.30×0.15× -100%
Interest Coverage◆ 455.22×89.28×72.67×8.80×56.92× +700%
Scale — latest FY
Revenue / Total Income₹3,822 Cr₹2,520 Cr₹6,929 Cr₹4,410 Cr₹4,620 Cr -17%
Net Income₹1,036 Cr₹722 Cr₹1,552 Cr₹554 Cr₹943 Cr +10%
Total Assets₹4,324 Cr₹4,922 Cr₹6,502 Cr₹5,905 Cr₹5,776 Cr -25%
EPS₹54.52——₹20.71₹20.71 +163%
Book Value per Share₹133.84——₹147.44₹147.44 -9%
◆ best value in the comp set per metric · Δ = subject vs average of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.